Eli Lilly and Co

LLY

Company Profile

  • Business description

    Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

  • Contact

    Lilly Corporate Center
    IndianapolisIN46285
    USA

    T: +1 317 276-2000

    E: [email protected]

    https://www.lilly.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2026

    Employees

    50,000

Eli Lilly and Co News & Analysis

stocks

Eli Lilly receives FDA approval to add another oral GLP-1 to market

Wide moat Eli Lilly receives FDA approval for obesity pill.
markets

Q2 2026 US stock market outlook: Don’t panic, readjust

Use the volatility to your advantage; where to harvest gains and where to redeploy.
stocks

Eli Lilly earnings: Revenue increases reflect global demand for oral obesity therapies

We’ve raised our fair value estimate of Lilly stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,168.7033.000.36%
CAC 408,425.130.000.00%
DAX 4024,702.24547.772.27%
Dow JONES (US)49,447.43868.711.79%
FTSE 10010,667.6377.640.73%
HKSE26,160.33233.93-0.89%
NASDAQ24,468.48365.781.52%
Nikkei 22558,475.901,042.44-1.75%
NZX 50 Index12,905.67160.39-1.23%
S&P 5007,126.0684.781.20%
S&P/ASX 2008,946.9036.800.41%
SSE Composite Index4,051.434.12-0.10%

Market Movers